3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
13
Triple Negative Breast Neoplasms
5
Neoplasm Metastasis
3
Urinary Bladder Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma
1
Refractory Solid Tumors
1
Liposarcoma
1
HR+HER2- Breast Cancer
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
12
Cisplatin
11
Specimen Handling
9
Bevacizumab
7
Brachytherapy
6
Platinum
5
Paclitaxel
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Human Papillomavirus DNA Tests
5
Colposcopy
5
Carboplatin
5
atezolizumab
4
Gemcitabine
4
Fulvestrant
4
Surveys and Questionnaires
3
Radiotherapy
3
Radiation Dose Hypofractionation
3
Radiation
3
Drug Therapy
3
Blood Specimen Collection
3
1,2-diaminocyclohexaneplatinum II citrate
3
tisotumab vedotin
2
palbociclib
2
lenvatinib
2
Topotecan
2
Restraint, Physical
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Magnetic Resonance Imaging
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
eribulin
×
90 days
×
Clear all
No trials found.